The antibiotic minocycline prevents methamphetamine-induced rewarding effects in mice
Highlights
► Methamphetamine (METH) induced rewarding effects in rodents and humans. ► Minocycline blocked METH-induced rewarding effects in mice. ► Minocycline blocked METH-induced release of dopamine in nucleus accumbens. ► Minocycline may be a potential therapeutic drug for METH dependence.
Introduction
Abuse of methamphetamine (METH) is a worldwide, public health problem (Hashimoto, 2007, Gonzales et al., 2010, Karila et al., 2010, Chen et al., 2010). The abuse of METH has significant psychiatric and medical consequences, including psychosis, dependence, overdose, and death. However, there are currently no pharmacological treatments for METH-induced symptoms (Hashimoto, 2007, Sofuoglu and Sewell, 2009, Gonzales et al., 2010, Karila et al., 2010, Sofluoglu, 2010, Chen et al., 2010).
Minocycline is a second-generation tetracycline that readily crosses the blood–brain barrier, and has powerful anti-inflammatory and neuroprotective properties (Domercq and Matute, 2004, Hashimoto, 2007, Chen et al., 2010). Previously, we reported that minocycline attenuated hyperlocomotion and the development of behavioral sensitization in mice, after the administration of METH (Zhang et al., 2006a). Furthermore, the reduction of dopamine (DA) and DA transporter (DAT) in the striatum of mouse and monkey brains associated with repeated METH administration, was significantly attenuated by subsequent treatment with minocycline (Zhang et al., 2006a, Hashimoto et al., 2007). Moreover, minocycline ameliorated 3,4-methylenedixoymethamphetamine (MDMA)-induced neurotoxicity of serotonergic neurons within mouse brains (Zhang et al., 2006b). It has also been reported that minocycline alleviated symptoms (e.g., hyperlocomotion, prepulse inhibition deficits, cognitive deficits) in mouse and rat models of schizophrenia, after the administration of N-methyl-d-aspartate (NMDA) receptor antagonists, such as, phencyclidine (PCP) and dizocilpine (Fujita et al., 2008, Zhang et al., 2007, Levkovitz et al., 2007). These findings suggest that minocycline may represent a promising therapeutic drug, for the treatment of long-term symptoms associated with METH abuse (Hashimoto, 2007, Hashimoto, 2008a, Chen et al., 2010).
In this study, we examined the effect of minocycline on METH-induced rewarding effects in mice, using the conditioned place preference (CPP) paradigm. We also examined the effects of minocycline on METH induced increases of extracellular levels of DA in the nucleus accumbens, since DA levels in this brain region play an important role in METH-induced rewarding effects (Ikemoto, 2007).
Section snippets
Animals
C57BL/6 mice (6 weeks old) weighing 25–30 g were purchased from SLC Japan (Hamamatsu, Shizuoka, Japan). The mice were housed in clear polycarbonate cages (22.5 × 33.8 × 14.0 cm) in groups of 5 or 6 per cage, under a controlled 12/12-h light–dark cycle (lights on from 7:00 AM to 7:00 PM), at a room temperature of 23 ± 1 °C and humidity of 55 ± 5%. The mice were given free access to water and food pellets. The experimental procedure was approved by the Animal Care and Use Committee of Chiba University.
Conditioned place preference (CPP)
The
Effects of minocycline on METH-induced rewarding effects in mice
We investigated the effects of minocycline on the rewarding effects of METH, using the CPP paradigm, which measures the rewarding properties of abused drugs. One-way ANOVA revealed significant differences among the four groups (df = 3.87, F = 5.402, p = 0.002)(Fig. 2). Post hoc analysis showed that METH (1.0 mg/kg, SC) significantly increased CPP scores in mice, compared with the vehicle-treated group. When mice were treated with minocycline (40 mg/kg, IP) 30 min before receiving METH (1.0 mg/kg, SC),
Discussion
In this study, we found that minocycline attenuated both METH-induced rewarding effects and the marked increases of extracellular DA in the nucleus accumbens, induced by METH administration. It is well known that increased DA signaling in the nucleus accumbens after METH exposure plays an important role in the development of METH-induced rewarding effects (Ikemoto, 2007, Lüscher and Malenka, 2011). Therefore, it is likely, that by inhibiting the increases in extracellular DA within the nucleus
Conclusion
This study suggests that minocycline can block METH-induced rewarding effects in mice. Therefore, minocycline would appear to be a potential therapeutic drug for METH use disorder, although further studies of minocycline in patients with METH use disorder will be necessary
Acknowledgments
The authors thank Dr. M. Funada (National Center of Neurology and Psychiatry, Tokyo, Japan) and Dr. Y. Takamatsu (Tokyo Institute of Psychiatry, Tokyo, Japan) for their invaluable advice on the CPP paradigm. This study is supported partly by a grant for Intramural Research Grant (19-2) for Neurological and Psychiatric Disorders of NCNP, Japan (to K.H.) and a grant from Japan China Medical Association (to K.H.). The authors have no financial interests or conflicts of interest to declare.
References (29)
- et al.
Possible anti-catatonic effects of minocycline in patients with schizophrenia
Prog Neuropsychopharmacol Biol Psychiatry
(2007) - et al.
Functional neuroimaging of minocycline's effect in a patient with schizophrenia
Prog Neuropsychopharmacol Biol Psychiatry
(2010) - et al.
Neuroprotection by tetracyclines
Trends Pharmacol Sci
(2004) - et al.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
Prog Neuropsychopharmacol Biol Psychiatry
(2008) Microglial activation in schizophrenia and minocycline treatment
Prog Neuropsychopharmacol Biol Psychiatry
(2008)Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatment
Prog Neuropsychopharmacol Biol Psychiatry
(2010)- et al.
Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a PET study in conscious monkeys
Biol Psychiatry
(2007) Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex
Brain Res Rev
(2007)- et al.
Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia
Brain Res
(2007) - et al.
Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling
Neuron
(2011)
Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine
Prog Neuropsychopharmacol Biol Psychiatry
Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain
Eur J Pharmacol
Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence
Curr Drug Abuse Rev
The mouse brain in stereotaxic coordinates
Cited by (43)
Neuroimmune modulators as novel pharmacotherapies for substance use disorders
2024, Brain, Behavior, and Immunity - HealthNeuronal activation of nucleus accumbens by local methamphetamine administration induces cognitive impairment through microglial inflammation in mice
2024, Journal of Pharmacological SciencesStress- and drug-induced neuroimmune signaling as a therapeutic target for comorbid anxiety and substance use disorders
2022, Pharmacology and TherapeuticsControl of complex behavior by astrocytes and microglia
2022, Neuroscience and Biobehavioral ReviewsMinocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users
2021, Pharmacology Biochemistry and BehaviorMicroglial alterations induced by psychoactive drugs: A possible mechanism in substance use disorder?
2019, Seminars in Cell and Developmental BiologyCitation Excerpt :In mice, the concomitant administration of METH (1.0 mg/kg, subcutaneous (s.c.) and minocycline (40 mg/kg, i.p.) during the conditioning phase in a CPP protocol tempered their preference for the METH-paired compartment. Notably, minocycline mitigated the increase in extracellular DA levels in the NAc that were induced by a single dose of METH (1.0 mg/kg, s.c.) [11]. Cocaine.